avibactam/ceftazidime (Avycaz)
Jump to navigation
Jump to search
Indications
- complicated intra-abdominal infections
- Avycaz used with metronidazole
- complicated urinary tract infections
Contraindications
- caution in patients with renal impairment
Dosage
Vials contain Avycaz 2.5 gram, equivalent to ceftazidime 2 gram & avibactam 0.5 gram[3]
Dosage adjustment in renal failure
- 1.25 g every 8 hours for CrCl of 31-50 mL/min
- 0.94 g every 12 hours for CrCl of 16 to 30 mL/min
- 0.94 g every 24 hours for CrCl of 6 to 15 mL/min
- 0.94 g every 48 hours for CrCl < 6 mL/min
Adverse effects
- anxiety, constipation, nausea, vomiting
- seizures may occur in patients with renal impairment
- Stevens-Johnson syndrome, toxic epidermal necrolysis & anaphylaxis may occur in patients with penicillin allergies[1]
Mechanism of action
- cephalosporin, beta-lactamase inhibitor combination
Notes
- distributed by Forest Pharmaceuticals Inc
More general terms
Components
References
- ↑ 1.0 1.1 Kelley KJ, Sofair A, Chavey WE New Combo Antibacterial Approved for Complicated Intra-Abdominal Infections, UTIs Physician's First Watch, Feb 27, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release. February 25, 2015 FDA approves new antibacterial drug Avycaz http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm - ↑ Prescriber's Letter 23(3): 2015 New Drug: Avycaz (Ceftazidime/Avibactam) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=310525&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 FDA Safety Alert. Sept 22, 2015 Avycaz (ceftazidime and avibactam): Drug Safety Communication
Dose Confusion and Medication Errors http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm463595.htm